Wed. Jun 7th, 2023

TAIPEI, April 17, 2023 /PRNewswire/ — Foresee Prescription drugs Co., Ltd. (6576.TWO) (“Foresee”), publicizes right this moment that Bassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Medical Growth.

Dr. Bassem Elmankabadi is a Board Licensed Surgeon with over 17 years of scientific background and expertise within the pharmaceutical business, together with a number of scientific management roles at Amgen (NASDAQ: AMGN), FibroGen (NASDAQ: FGEN), and Blade Therapeutics. He had a few years of expertise main a number of well being businesses’ face-to-face interactions and negotiations, leading to an settlement on 4 Medical Growth Plans for Section 2 and three scientific research throughout a number of indications of Cudetaxestat (ATX inhibitor) and Pamrevlumab (CTGF inhibitor).

Previous to Blade, FibroGen, and Amgen, he was a surgeon, medical director, scientific teacher at UCLA in Los Angeles for the KRAS oncogene program. He spent 5+ years working for a CRO on a number of Section 2/3 research in retinal ailments. Dr. Elmankabadi obtained his Physician of Drugs & Surgical procedure and a grasp’s diploma in ophthalmology from the College of Cairo Faculty of Drugs, Cairo. Egypt. He accomplished an internship in trauma surgical procedure on the State College of New York Downstate Medical Middle School of Drugs and normal surgical procedure residency at Brooklyn Hospital Middle, Faculty of Drugs at Mount Sinai, New York.

“We’re thrilled to have Dr. Elmankabadi be a part of our crew,” mentioned Dr. Ben Chien, Chairman and CEO of Foresee Prescription drugs. “His intensive scientific growth expertise and management expertise within the pharmaceutical business shall be invaluable as we proceed to advance our pipeline of modern drug candidates.”

“I’m happy to affix Foresee and stay up for working with the crew to construct on the success story of transiting Foresee and highlighting our science and scientific technique to the scientific group and well being authorities,” mentioned Dr. Elmankabadi.

About Foresee Prescription drugs Co. Ltd.
Foresee is a Taiwan and US-based biopharmaceutical firm listed on the Taipei Alternate (6576.TWO). Foresee’s R&D efforts are centered in two key areas, specifically its distinctive stabilized injectable formulation (SIF) depot supply know-how with derived drug merchandise focusing on specialty markets and secondly, its transformative preclinical and scientific first-in-class NCE packages focusing on uncommon and extreme illness areas with excessive unmet wants.

Foresee’s product portfolio consists of late and early-stage packages. CAMCEVI® 42 mg, for the therapy of superior prostate most cancers, is now authorised within the U.S., Canada, and EU, and launched within the U.S. in April, 2022. Moreover, U.S. and EU regulatory submissions are below preparation for CAMCEVI® 21 mg, the U.S. regulatory submission is anticipated in 2024. The second indication of CAMCEVI® 42 mg– central precocious puberty (CPP), the section 3 scientific examine is presently being initiated. FP-025 – a extremely selective oral MMP-12 inhibitor focusing on inflammatory and fibrotic ailments, a Section 2 proof-of-concept examine in allergic asthmatic sufferers, the evaluation of major endpoint knowledge has been accomplished with constructive end result, additional secondary endpoints, together with biomarker evaluation is presently ongoing. FP-045 – a extremely selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Section 1b/2 Fanconi Anemia examine is presently being initiated.


View authentic content material:

SOURCE Foresee Prescription drugs Co., Ltd.

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *